HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Consumer Health Is “Logical Extension” Of Rx – CEO McKinnell

This article was originally published in The Tan Sheet

Executive Summary

Pfizer is emphasizing the strategic importance of its OTC business for patent-expired Rx products as the firm nears the period when it could divest any of its businesses following the Warner-Lambert merger

You may also be interested in...



Warner-Lambert

First-year sales of Cool Mint Listerine PocketPaks strips, which launched nationwide Oct. 9, expected to exceed $100 mil., company says. W-L and ad agency J. Walter Thompson (New York) plan to launch $40 mil. campaign including TV, other mediums within next few weeks (1"The Tan Sheet" July 9, p. 4). PocketPaks, which kill odor-causing mouth germs, received promotional support from network TV's Regis & Kelly show when exuberant co-host Kelly Ripa tried strips on air and gave them an enthusiastic review. Over the last few months, W-L has sent free samples to several TV stations, professional sports teams and modeling agencies across the country, firm says

OTC Sale Of Rx Allergy Drugs Would Be Safer, Cut Costs - Health Plan

Nonsedating antihistamines classified as prescription drugs would be more appropriately sold as OTCs, Blue Cross of California Pharmacy VP Rob Seidman maintains in Jan. 12 letters sent to marketers of the drugs.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS130605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel